<DOC>
	<DOCNO>NCT01686620</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy BIOD-123 compare insulin lispro ( Humalog® ) use part basal-bolus regimen patient type 1 diabetes .</brief_summary>
	<brief_title>A Study Evaluating Safety Efficacy BIOD-123 Compared Insulin Lispro ( Humalog® )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Established clinical diagnosis type 1 diabetes , consistent ADA classification criterion ( Diabetes Care 35 : S64S71 , 2012 ) , 1 year . Age : 18 year old , old . Body Mass Index : 18 35 kg/m2 , inclusive . Willing use insulin glargine basal insulin throughout duration trial . Willingness use insulin pump treatment use study glucose meter CGM device duration trial . History known hypersensitivity component study medication Treatment pramlintide GLP1 analog within 30 day screen anticipated use medication course study . Treatment oral intravenous corticosteroid last 3 month prior screen . Standard dose inhalational corticosteroid use part long term treatment regimen allow . Consistent recent hypoglycemic unawareness within last six month History two severe hypoglycemic event within six month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Mealtime insulin</keyword>
	<keyword>Ultra-rapid acting insulin</keyword>
	<keyword>Prandial insulin</keyword>
</DOC>